Snippets from article:
“From a patient-advocate point of view, we are completely supportive of the CEO’s decision to terminate Dr. Krieg,” Leffler’s friend and ally, Christine McSherry, told the Boston Business Journal. “We have complete confidence in [Garabedian].” Like Aidan Leffler, McSherry’s wheelchair-bound son, Jett, 19, has DMD and might benefit from eteplirsen.
While Krieg was a senior figure at Sarepta, he wasn’t centrally involved in the eteplirsen program or dealings with the FDA, according to former colleagues. He focused on more basic research. Corporate reshuffling isn’t pleasant, but in the big scheme of things, it’s not as important as whether a life-extending drug gets to people who need it. Krieg’s departure may eliminate a source of distraction and allow the company to move beyond a period of infighting, one longtime Sarepta investor told me."
Mindy Leffler is understandably anxious. She’s waiting to enroll Aidan in the next eteplirsen trial, which Sarepta has said will start in the near future. “Every week that goes by, my son gets a little weaker,” she said. “I wish the executives who are worried about management styles would spend some time in my home.”
It’s time to set aside personal antagonisms at Sarepta and do the job, Leffler added. “Just get my kid the drug.”